A Study of Participants Undergoing Radial Head Replacement Using the DePuy Synthes Radial Head Replacement System for Partial Replacement of the Elbow Joint

Sponsor
DePuy Synthes Products, Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05415592
Collaborator
(none)
120
4
86
30
0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to establish survivorship defined by the cumulative incidence of revision over the first 6 months post-implantation.

Condition or Disease Intervention/Treatment Phase
  • Device: DePuy Synthes Radial Head Replacement System

Study Design

Study Type:
Observational
Anticipated Enrollment :
120 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Multi-Center, Post-Market, Single-Arm, Observational Clinical Follow-Up Study of Patients Undergoing Radial Head Replacement Using the DePuy Synthes Radial Head Replacement System for Partial Replacement of the Elbow Joint
Anticipated Study Start Date :
Oct 31, 2022
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2029

Arms and Interventions

Arm Intervention/Treatment
DePuy Synthes Radial Head Replacement System

Participants will undergo a radial head replacement or partial replacement of the elbow joint with the DePuy Synthes Radial Head Replacement System.

Device: DePuy Synthes Radial Head Replacement System
DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.

Outcome Measures

Primary Outcome Measures

  1. Device survivorship Over the First 6 Months Post-implantation [6 months post-implantation]

    Device survivorship is defined by the cumulative incidence of absence of revision. A revision is considered to be any procedure that involves removal of the implant (that is, removal of the Radial Head Prosthesis [RHP], replacement with another RHP or revision surgery to a total elbow arthroplasty).

Secondary Outcome Measures

  1. Number of Participant with Revision Radial Head Replacement (RHR) Surgery [Up to 4 years post surgery]

    Number of participants with revision RHR surgery will be reported. Revision surgery reasons include symptomatic aseptic loosening, elbow stiffness, persistent pain, infection, elbow instability, overlengthening, dissociation of the prosthesis, progressive symptomatic ulnohumeral degeneration, secondary fracture, heterotopic ossification, osteoarthritis, erosions of the capitellum, or other implant-related complications.

  2. Assessment of Radiographic Parameters: Mason Classification of Radial Head Fractures [Preoperative, Operative, Discharge (up to Day 6)]

    Mason classification system will be used for the classification of radial head fractures. It includes four radial head fracture types. Mason Type I are non-displaced radial head fractures (or small marginal fractures), Mason Type II are partial articular fractures with displacement, Mason Type III are comminuted fractures involving the entire radial head, and Mason Type IV are fractures of the radial head with dislocation of the elbow joint.

  3. Assessment of Radiographic Parameters: Radiolucency [At Months 6, 12, and 24]

    Radiolucency will be assessed based on the number of zones involved and the amount of lucency (in millimeters) observed. Radiolucency is classified as: a) None; b) Mild: one or two zones involved by lucent lines of less than (<) 2 millimeters (mm) in thickness; c) Moderate: three to six zones involved or the lucency of greater than or equal to (>=) 2 mm in thickness and d) Severe: all seven zones involved.

  4. Assessment of Radiographic Parameters: Radiocapitellar Alignment [Operative at Week 2, and 6, Months 3, 6, 12, 24, and 48 post operative]

    Radiocapitellar alignment will be determined. The position of the radial head prosthesis is assessed on a lateral X-ray based on the intersection between the axis of the prosthetic shaft and the center of the capitellum. The calculation is based on the quotient of the diameter of the trochlea humeri and the axis of the prosthesis.

  5. Assessment of Radiographic Parameters: Ulnohumeral Degeneration [Operative at Week 2, and 6, Months 3, 6, 12, 24, and 48 post operative]

    Ulnohumeral degeneration will be assessed. The degree of ulnohumeral degeneration is classified with the system described by Broberg and Morrey as Grade 0 (normal joint), Grade 1 (slight joint space narrowing with minimum osteophyte formation), Grade 2 (moderate joint space narrowing with moderate osteophyte formation) or Grade 3 (severe degenerative changes with gross destruction of the joint).

  6. Assessment of Radiographic Parameters: Osteoarthritis [At Week 2, and 6, Months 3, 6, 12, 24, and 48]

    Osteoarthritis (in the radio-capitellar joint) will be assessed. Osteoarthritis is evaluated as yes/no, if yes, the location will be described (that is., medial, lateral or both).

  7. Assessment of Radiographic Parameters: Heterotopic Ossification [At Week 2, and 6, Months 3, 6, 12, 24, and 48]

    Heterotopic ossification will be determined and reported. Heterotopic ossification is classified as present (that is, anterior-posterior, medial-lateral) or absent.

  8. Assessment of Radiographic Parameters: Osteopenia, and/or Capitellar Abrasion [At Week 2, and 6, Months 3, 6, 12, 24, and 48]

    Osteopenia, and/or capitellar abrasion will be determined and reported. Capitellar osteopenia and/or abrasion is classified as none, mild, moderate, or severe.

  9. Assessment of Radiographic Parameters: Overlengthening [Operative at Months 6, 12, and 24 post operative]

    Overlengthening will be determined and reported. Overlengthening is assessed on the intra- or postoperative, 6-, 12- and 24 months Antero-Posterior (AP) and lateral X-rays (evidence of overstuffing).

  10. Assessment of Radiographic Parameters: Joint incongruity [Operative at Week 2, and 6, Months 3, 6, 12, 24 and 48 post operative]

    Joint incongruity will be determined and reported. Joint incongruity is assessed as yes/no.

  11. Mayo Elbow Performance Index (MEPI) Score [Week 2 and 6, Months 3, 6, 12, 24, and 48]

    MEPI is also known as Mayo Elbow Performance Score (MEPS). MEPI is used to evaluate the clinical outcomes for a variety of elbow disorders such as elbow fractures and dislocations. The MEPI is a validated hundred-point system based upon pain (forty five points), range of motion (twenty points), stability (ten points) and daily function (twenty five points) The scale ranges from 0 to 100, with a higher score indicating a better outcome.

  12. Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) Score [Week 2 and 6, Months 3, 6, 12, 24, and 48]

    QuickDASH questionnaire has 30-items, which includes 21 items for physical function, 6 for symptoms, and 3 for social roles. Quick DASH is a shorter version, developed for less burden to the responder. It consists of 11 items out of the original 30 questions of the DASH. QuickDASH is scored between 0 (no disability) to 100 (most severe disability), with lower scores indicating better overall wellness.

  13. Elbow Range of Motion (ROM) [Week 2 and 6, Months 3, 6, 12, 24, and 48]

    Elbow ROM of both sites (injured side and contralateral side) will be assessed according to standard of care practices for elbow flexion, elbow extension, forearm supination, and forearm pronation.

  14. Grip Strength of the Injured Limb Compared to the Contralateral Side [At Week 6, Months 6, 12, 24 and 48]

    The grip strength (if available) will be assessed with dynamometer following the standardized testing protocol recommended by the American Society of Hand Therapists (ASHT). For measurements, the participants would be in a comfortable sitting position in a chair without arm rests, with feet fully resting on the floor, hips as far back in the chair as possible, and the hips and knees positioned at approximately 90 degrees. Grip force should be applied smoothly, without rapid wrenching or jerking motion. (No correction for hand dominance will be performed because this effect varies substantially among users. Assessment will be also performed on the unaffected side using the same method.

  15. European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Scale Score [Preoperative, Week 6, Months 6, 12, 24, and 48]

    EQ-5D-5L questionnaire includes five questions (descriptive system: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a visual analog scale to rate the current health status. The resulting scores were converted into a single index score that ranged from -0.281 to 1, where higher score indicates better health. Values lower than 0 represent states considered to be worse than death.

  16. Local Pain Assessed by Numerical Rating Scale (NRS) Score [Week 2 and 6, Months 3, 6, 12, 24, and 48]

    Local pain intensity levels over the previous 24 hours will be assessed with the Numerical Rating Scale (NRS). The scale range goes from 0 (no pain) to 10 (worst imaginable pain). A higher value correlates with greater pain.

  17. Number of Participants who Return to Work and Sport [Week 2 and 6, Months 3, 6, 12, 24, 36 and 48]

    Number of participants who return to work and Sport will be assessed as yes/no.

  18. Number of Participants with Device and/or Procedure-related Adverse Events (AEs) [Operative, Discharge (up to Day 6), Week 2, 6, Months 3, 6, 12, 24, 36, and 48]

    Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in participants, users or other persons, whether or not related to investigational medical device, the Radial Head Replacement System, and whether anticipated or unanticipated.

  19. Number of Participants with Device and/or Procedure-related Serious Adverse Events (SAEs) [Operative, Discharge (up to Day 6), Week 2, 6, Months 3, 6, 12, 24, 36, and 48]

    SAEs are defined as any device and or procedure related adverse event that: 1. Led to death; 2. Serious deterioration in the health of the subject, that resulted in any of the following: a. life-threatening illness or injury, b. permanent impairment of a body structure or a body function, c. hospitalization or prolongation of existing hospitalization, d. medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, e. chronic disease; 3. Led to fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

  20. Number of Participants with Revision/Reoperations [Operative, Discharge (up to Day 6), Week 2, 6, Months 3, 6, 12, 24, 36, and 48]

    Number of participants with revision/reoperation will be reported. A revision is considered to be any procedure that involves removal of the implant (that is, removal of the RHP, replacement with another RHP or revision surgery to a total elbow arthroplasty). Reoperation is defined as a second operation involving the DePuy Synthes Radial Head Replacement System at the index site and after the index surgery that does not include removal or replacement of the implanted Radial Head Prosthesis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female - skeletally mature adult (aged 22 or older)

  • Participant, who in the opinion of the Investigator, is able to understand the purpose of the study and is willing to return for all the required post-operative standard of care follow-up visits and have their data collected

  • Participant who is willing to give voluntary, written informed consent to participate in this clinical investigation and authorize the transfer of his/her information to the Sponsor

Any one of below:
  • Primary replacement after fracture of the radial head

  • Participant needing a partial radial head replacement for degenerative or post-traumatic conditions presenting pain, crepitation, and decreased motion at the radio-humeral and/or proximal radio-ulnar joint with: i) joint destruction and/or subluxation visible on x-ray and/or ii. resistance to conservative treatment

  • Symptomatic sequelae after radial head resection

  • Revision following failed radial head arthroplasty

Exclusion Criteria:
  • Dislocations of radius on ulna that would not allow a radio-humeral articulation

  • Rheumatoid arthritis

  • Infection, sepsis, and osteomyelitis

  • Uncooperative participant or participant with neurologic disorders who is incapable of following directions, osteoporosis, metabolic disorders which may impair bone formation, osteomalacia, distant foci of infections which may spread to the implant site, rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram

  • Participants with limited life expectancy due to significant medical co-morbidity

  • Presence of major vascular or major nerve injury (radial, ulnar, medial, musculocutaneous)

  • Women who are pregnant or lactating

  • Unable to comply with study requirements example, with maintaining follow-up

  • Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims

  • Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months

  • Demented or unable to provide informed consent

  • Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete participant reported questionnaires or be compliant with follow-up requirements

Contacts and Locations

Locations

Site City State Country Postal Code
1 MetroHealth Medical Center Cleveland Ohio United States 44109
2 Slocum Research & Education Foundation Eugene Oregon United States 97401
3 Inova Orthopaedics - Fairfax Falls Church Virginia United States 22042
4 Glasgow Royal Infirmary (NHS Greater Glasgow & Clyde) Glasgow United Kingdom G40SF

Sponsors and Collaborators

  • DePuy Synthes Products, Inc.

Investigators

  • Study Director: DePuy Synthes Products, Inc. Clinical Trial, DePuy Synthes Products, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
DePuy Synthes Products, Inc.
ClinicalTrials.gov Identifier:
NCT05415592
Other Study ID Numbers:
  • DST202002
  • DST202002
First Posted:
Jun 13, 2022
Last Update Posted:
Aug 9, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by DePuy Synthes Products, Inc.

Study Results

No Results Posted as of Aug 9, 2022